The role of fibrate treatment in dyslipidemia: An overview

Current Pharmaceutical Design

Volumn 19, Issue 17, 2013, Pages 3124-3131

  Katsiki, Niki ^a   Nikolic, Dragana ^b   Montalto, Giuseppe ^b   Banach, Maciej ^c   Mikhailidis, Dimitri P ^d   Rizzo, Manfredi ^b,e  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF PALERMO   (Italy)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e Euro Mediterranean Institute of Science and Technology   (Italy)

Author keywords

Cardiovascular risk; Diabetes; Dyslipidemia; Fibrates

Indexed keywords

ADIPOCYTOKINE; ATORVASTATIN; ATORVASTATIN PLUS FENOFIBRATE; BEZAFIBRATE; CIPROFIBRATE; COLESEVELAM; EZETIMIBE; FENOFIBRATE; FENOFIBRATE PLUS PRAVASTATIN; FIBRATE PLUS STATINS; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PLACEBO; PRAVASTATIN; SIMVASTATIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MIXTURE; DYSLIPIDEMIA; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN SENSITIVITY; KIDNEY DYSFUNCTION; LIPID METABOLISM; METABOLIC SYNDROME X; MYOPATHY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DYSLIPIDEMIAS; FIBRIC ACIDS; HUMANS; HYPOLIPIDEMIC AGENTS; TRIGLYCERIDES;

EID: 84878652813     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319170020     Document Type: Review

References (137)

1. Organization WH. World Health Statistics. 2012; Available from: http://www.who.int/gho/publications/world_health_statistics/EN_ WHS2012_Full.pdf.
2. Gotto AM, Jr., Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. The American journal of cardiology. 2012; 110(1 Suppl): 3A-14A.
3. Milionis HJ, Elisaf MS, Mikhailidis DP. Lipid abnormalities and cardiovascular risk in the elderly. Current medical research and opinion. 2008; 24(3): 653-7.
4. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European heart journal. 2012; 33(13): 1635-701.
5. Athyros VG, Katsiki N, Karagiannis A, et al. Should raising highdensity lipoprotein cholesterol be a matter of debate? J Cardiovasc Med (Hagerstown). 2012; 13(4): 254-9.
6. Florentin M, Liberopoulos EN, Mikhailidis DP, et al. Emerging options in the treatment of dyslipidemias: a bright future? Expert opinion on emerging drugs. 2011; 16(2): 247-70.
7. Oh RC, Lanier JB. Management of hypertriglyceridemia. American family physician. 2007; 75(9): 1365-71.
8. Kolovou GD, Mikhailidis DP, Nordestgaard BG, et al. Definition of postprandial lipaemia. Current vascular pharmacology. 2011; 9(3): 292-301.
9. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Current vascular pharmacology. 2011; 9(3): 258-70.
10. Moutzouri E, Kei A, Elisaf MS, et al. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid. Vascular health and risk management. 2010; 6: 525-39.
11. Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. The Journal of clinical investigation. 1995; 95(2): 705-12.
12. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998; 98(19): 2088-93.
13. Boitier E, Gautier JC, Roberts R. Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease. Comparative hepatology. 2003; 2(1): 3.
14. Lamers C, Schubert-Zsilavecz M, Merk D. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present). Expert opinion on therapeutic patents. 2012; 22(7): 803-41.
15. Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007; 115(4): 518-33.
16. Soskic SS, Dobutovic BD, Sudar EM, et al. Peroxisome proliferator-activated receptors and atherosclerosis. Angiology. 2011; 62(7): 523-34.
17. Benz V, Kintscher U, Foryst-Ludwig A. Sex-Specific Differences in Type 2 Diabetes Mellitus and Dyslipidemia Therapy: PPAR Agonists. Handbook of experimental pharmacology. 2012; (214): 387-410.
18. Clockaerts S, Bastiaansen-Jenniskens YM, Feijt C, et al. Cytokine production by infrapatellar fat pad can be stimulated by interleukin 1beta and inhibited by peroxisome proliferator activated receptor alpha agonist. Annals of the rheumatic diseases. 2012; 71(6): 1012-8.
19. Heller F, Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. European journal of clinical pharmacology. 1983; 25(1): 57-63.
20. Malmendier CL, Lontie JF, Delcroix C, et al. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration. Atherosclerosis. 1989; 77(2-3): 139-49.
21. Peters JM, Hennuyer N, Staels B, et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alphadeficient mice. The Journal of biological chemistry. 1997; 272(43): 27307-12.
22. Lamb RG, Koch JC, Bush SR. An enzymatic explanation of the differential effects of oleate and gemfibrozil on cultured hepatocyte triacylglycerol and phosphatidylcholine biosynthesis and secretion. Biochimica et biophysica acta. 1993; 1165(3): 299-305.
23. Lalloyer F, Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arteriosclerosis, thrombosis, and vascular biology. 2010; 30(5): 894-9.
24. Simo IE, Yakichuk JA, Ooi TC. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Atherosclerosis. 1993; 100(1): 55-64.
25. Simpson HS, Williamson CM, Olivecrona T, et al. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis. 1990; 85(2-3): 193-202.
26. Cavallero E, Piolot A, Jacotot B. Postprandial lipoprotein clearance in type 2 diabetes: fenofibrate effects. Diabete & metabolisme. 1995; 21(2): 118-20.
27. Martin G, Schoonjans K, Lefebvre AM, et al. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. The Journal of biological chemistry. 1997; 272(45): 28210-7.
28. Schoonjans K, Watanabe M, Suzuki H, et al. Induction of the acylcoenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. The Journal of biological chemistry. 1995; 270(33): 19269-76.
29. D'Costa MA, Angel A. Inhibition of hormone-stimulated lipolysis by clofibrate. A possible mechanism for its hypolipidemic action. The Journal of clinical investigation. 1975; 55(1): 138-48.
30. Caslake MJ, Packard CJ, Gaw A, et al. Fenofibrate and LDL metabolic heterogeneity in hypercholesterolemia. Arteriosclerosis and thrombosis: a journal of vascular biology / American Heart Association. 1993; 13(5): 702-11.
31. de Graaf J, Hendriks JC, Demacker PN, et al. Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment. Arteriosclerosis and thrombosis: a journal of vascular biology / American Heart Association. 1993; 13(5): 712-9.
32. Dachet C, Cavallero E, Martin C, et al. Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients. Atherosclerosis. 1995; 113(1): 1-9.
33. Tilly-Kiesi M, Tikkanen MJ. Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil. Journal of internal medicine. 1991; 229(5): 427-34.
34. Franceschini G, Lovati MR, Manzoni C, et al. Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction. Atherosclerosis. 1995; 114(1): 61-71.
35. Mann CJ, Yen FT, Grant AM, et al. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. The Journal of clinical investigation. 1991; 88(6): 2059-66.
36. Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. The Journal of clinical investigation. 1995; 96(2): 741-50.
37. Berthou L, Duverger N, Emmanuel F, et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. The Journal of clinical investigation. 1996; 97(11): 2408-16.
38. Vu-Dac N, Schoonjans K, Laine B, et al. Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. The Journal of biological chemistry. 1994; 269(49): 31012-8.
39. Bard JM, Parra HJ, Camare R, et al. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism: clinical and experimental. 1992; 41(5): 498-503.
40. Lussier-Cacan S, Bard JM, Boulet L, et al. Lipoprotein composition changes induced by fenofibrate in dysbetalipoproteinemia type III. Atherosclerosis. 1989; 78(2-3): 167-82.
41. Boden G, Chen X, Ruiz J, et al. Mechanisms of fatty acid-induced inhibition of glucose uptake. The Journal of clinical investigation. 1994; 93(6): 2438-46.
42. Koh EH, Kim MS, Park JY, et al. Peroxisome proliferatoractivated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Diabetes. 2003; 52(9): 2331-7.
43. Marx N, Duez H, Fruchart JC, et al. Peroxisome proliferatoractivated receptors and atherogenesis: regulators of gene expression in vascular cells. Circulation research. 2004; 94(9): 1168-78.
44. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. The Journal of clinical investigation. 1995; 95(5): 2409-15.
45. Kouroumichakis I, Papanas N, Zarogoulidis P, et al. Fibrates: therapeutic potential for diabetic nephropathy? European journal of internal medicine. 2012; 23(4): 309-16.
46. Kaur J, Reddy K, Balakumar P. The novel role of fenofibrate in preventing nicotine-and sodium arsenite-induced vascular endothelial dysfunction in the rat. Cardiovascular toxicology. 2010; 10(3): 227-38.
47. Wierzbicki AS, Clarke RE, Viljoen A, et al. Triglycerides: a case for treatment? Current opinion in cardiology. 2012; 27(4): 398-404.
48. McCullough PA, Ahmed AB, Zughaib MT, et al. Treatment of hypertriglyceridemia with fibric acid derivatives: impact on lipid subfractions and translation into a reduction in cardiovascular events. Reviews in cardiovascular medicine. 2011; 12(4): 173-85.
49. Loomba RS, Arora R. Prevention of cardiovascular disease utilizing fibrates--a pooled meta-analysis. American journal of therapeutics. 2010; 17(6): e182-8.
50. Wojczynski MK, Gao G, Borecki I, et al. Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study. Journal of lipid research. 2010; 51(11): 3316-23.
51. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primaryprevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. The New England journal of medicine. 1987; 317(20): 1237-45.
52. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. The New England journal of medicine. 1999; 341(6): 410-8.
53. Meade T, Zuhrie R, Cook C, et al. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002; 325(7373): 1139.
54. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366(9500): 1849-61.
55. de Faire U, Ericsson CG, Grip L, et al. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). European heart journal. 1996; 17 Suppl F: 37-42.
56. Frick MH, Syvanne M, Nieminen MS, et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation. 1997; 96(7): 2137-43.
57. Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 2003; 107(13): 1733-7.
58. Group BS. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000; 102(1): 21-7.
59. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010; 375(9729): 1875-84.
60. Rizos E, Mikhailidis DP. Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovascular research. 2001; 52(2): 199-207.
61. Krysiak R, Gdula-Dymek A, Okopien B. The Effect of Fenofibrate on Lymphocyte Release of Proinflammatory Cytokines and Systemic Inflammation in Simvastatin-Treated Patients with Atherosclerosis and Early Glucose Metabolism Disturbances. Basic & clinical pharmacology & toxicology. 2012.
62. Tziomalos K, Athyros VG, Karagiannis A, et al. Antiinflammatory effects of fibrates: an overview. Current medicinal chemistry. 2009; 16(6): 676-84.
63. Koh KK, Quon MJ, Shin KC, et al. Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia. Atherosclerosis. 2012; 220(2): 537-44.
64. Olukman M, Sezer ED, Ulker S, et al. Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats. Experimental diabetes research. 2010; 2010: 828531.
65. Dong Y, Steffen BT, Cao J, et al. Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants. Atherosclerosis. 2011; 214(2): 422-5.
66. Tziomalos K, Athyros VG. Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. International journal of nanomedicine. 2006; 1(2): 129-47.
67. Katsiki N, Yovos JG, Gotzamani-Psarrakou A, et al. Adipokines and vascular risk in type 2 diabetes mellitus. Angiology. 2011; 62(8): 601-4.
68. Wanders D, Plaisance EP, Judd RL. Pharmacological effects of lipid-lowering drugs on circulating adipokines. World journal of diabetes. 2010; 1(4): 116-28.
69. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, et al. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert opinion on therapeutic targets. 2011; 15(4): 401-20.
70. Koh KK, Quon MJ, Lim S, et al. Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia. Atherosclerosis. 2011; 214(1): 144-7.
71. Balakumar P, Kadian S, Mahadevan N. Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? Pharmacological research: the official journal of the Italian Pharmacological Society. 2012; 65(4): 430-6.
72. Jeanpierre E, Le Tourneau T, Zawadzki C, et al. Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits. Cardiovascular pathology: the official journal of the Society for Cardiovascular Pathology. 2009; 18(3): 140-7.
73. Bhateja DK, Dhull DK, Gill A, et al. Peroxisome proliferatoractivated receptor-alpha activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms. European journal of pharmacology. 2012; 674(1): 33-43.
74. Ouk T, Laprais M, Bastide M, et al. Withdrawal of fenofibrate treatment partially abrogates preventive neuroprotection in stroke via loss of vascular protection. Vascular pharmacology. 2009; 51(5-6): 323-30.
75. Wong TY, Simo R, Mitchell P. Fenofibrate-a potential systemic treatment for diabetic retinopathy? American journal of ophthalmology. 2012; 154(1): 6-12.
76. Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009; 373(9677): 1780-8.
77. Bonds DE, Craven TE, Buse J, et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia. 2012; 55(6): 1641-50.
78. Mychaleckyj JC, Craven T, Nayak U, et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes care. 2012; 35(5): 1008-14.
79. Ting RD, Keech AC, Drury PL, et al. Benefits and safety of longterm fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. Diabetes care. 2012; 35(2): 218-25.
80. Rizos E, Mikhailidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials. Int J Cardiol. 2002; 82(3): 199-207
81. Lopez-Huertas E. The effect of EPA and DHA on metabolic syndrome patients: a systematic review of randomised controlled trials. The British journal of nutrition. 2012; 107 Suppl 2: S185-94.
82. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369(9567): 1090-8.
83. Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008; 200(1): 135-40.
84. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSIPrevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999; 354(9177): 447-55.
85. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA: the journal of the American Medical Association. 2012; 308(10): 1024-33.
86. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes care. 2002; 25(7): 1198-202.
87. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism: clinical and experimental. 2005; 54(8): 1065-74.
88. Athyros VG, Tziomalos K, Karagiannis A, et al. Statin-fibrate combination for mixed dyslipidaemia: a limited option? Current medical research and opinion. 2010; 26(9): 2137-40.
89. Roth EM, McKenney JM, Kelly MT, et al. Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study. American journal of cardiovascular drugs: drugs, devices, and other interventions. 2010; 10(3): 175-86.
90. Jones PH, Davidson MH, Goldberg AC, et al. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. Journal of clinical lipidology. 2009; 3(2): 125-37.
91. Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. The American journal of cardiology. 2009; 103(4): 515-22.
92. Derosa G, Cicero AE, Bertone G, et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clinical therapeutics. 2004; 26(10): 1599-607.
93. Farnier M, Ducobu J, Bryniarski L. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy. The American journal of cardiology. 2010; 106(6): 787-92.
94. Farnier M, Ducobu J, Bryniarski L. Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy. Current medical research and opinion. 2011; 27(11): 2165-73.
95. Davidson MH, Rooney MW, Drucker J, et al. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clinical therapeutics. 2009; 31(12): 2824-38.
96. Farnier M. Pravastatin and fenofibrate in combination (Pravafenix(R) for the treatment of high-risk patients with mixed hyperlipidemia. Expert review of cardiovascular therapy. 2012; 10(5): 565-75.
97. Products A. A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease. ClinicalTrials. gov; 2012; Available from: http://www.clinicaltrials.gov/ct2/show/NCT01674712?term=simva statin+fenofibrate+tablet&rank=1.
98. Tenenbaum A, Medvedofsky D, Fisman EZ, et al. Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data. PloS one. 2012; 7(4): e35298.
99. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. The New England journal of medicine. 2010; 362(17): 1563-74.
100. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. The American journal of cardiology. 2005; 95(1): 120-2.
101. Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review. Current medical research and opinion. 2003; 19(3): 155-68.
102. Agouridis AP, Filippatos TD, Tsimihodimos V, et al. Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism. Expert review of cardiovascular therapy. 2011; 9(3): 355-66.
103. Farnier M, Freeman MW, Macdonell G, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. European heart journal. 2005; 26(9): 897-905.
104. Agouridis AP, Filippatos TD, Derdemezis CS, et al. Combination of fenofibrate with non-statin drug regimens. Current pharmaceutical design. 2010; 16(30): 3401-16.
105. Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundamental & clinical pharmacology. 2010; 24(1): 19-28.
106. Farnier M. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing. Vascular health and risk management. 2008; 4(5): 991-1000.
107. Florentin M, Liberopoulos EN, Mikhailidis DP, et al. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Current medical research and opinion. 2008; 24(4): 995-1009.
108. McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Current medical research and opinion. 2005; 21(9): 1403-12.
109. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Current medical research and opinion. 2005; 21(12): 1997-2006.
110. Tolentino MC, Ferenczi A, Ronen L, et al. Combination of gemfibrozil and orlistat for treatment of combined hyperlipidemia with predominant hypertriglyceridemia. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2002; 8(3): 208-12.
111. Balasubramanyam A, Coraza I, Smith EO, et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive, " a randomized, controlled trial. The Journal of clinical endocrinology and metabolism. 2011; 96(7): 2236-47.
112. Superko HR, Garrett BC, King SB, 3rd, et al. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia. The American journal of cardiology. 2009; 103(3): 387-92.
113. Krauss RM, Burke DJ. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. Journal of lipid research. 1982; 23(1): 97-104.
114. Rizzo M, Berneis K. Should we measure routinely the LDL peak particle size? International journal of cardiology. 2006; 107(2): 166-70.
115. Rizzo M, Berneis K. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? Journal of atherosclerosis and thrombosis. 2005; 12(5): 237-9.
116. Rizzo M, Berneis K. Who needs to care about small, dense lowdensity lipoproteins? International journal of clinical practice. 2007; 61(11): 1949-56.
117. El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of lowdensity lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Journal of the American College of Cardiology. 2007; 49(5): 547-53.
118. Rizzo M, Berneis K. The clinical significance of the size of lowdensity-lipoproteins and the modulation of subclasses by fibrates. Current medical research and opinion. 2007; 23(5): 1103-11.
119. Superko HR, Berneis KK, Williams PT, et al. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. The American journal of cardiology. 2005; 96(9): 1266-72.
120. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992; 85(1): 37-45.
121. Rizzo M, Rini GB, Berneis K. Effects of statins, fibrates, rosuvastatin, and ezetimibe beyond cholesterol: the modulation of LDL size and subclasses in high-risk patients. Advances in therapy. 2007; 24(3): 575-82.
122. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Current vascular pharmacology. 2011; 9(5): 533-71.
123. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Current vascular pharmacology. 2011; 9(5): 531-2.
124. Watts GF, Mandalia S, Brunt JN, et al. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism: clinical and experimental. 1993; 42(11): 1461-7.
125. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006; 113(12): 1556-63.
126. Homma Y, Ozawa H, Kobayashi T, et al. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis. 1994; 106(2): 191-201.
127. Ikewaki K, Noma K, Tohyama J, et al. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study. International journal of cardiology. 2005; 101(3): 441-7.
128. Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). Journal of the American College of Cardiology. 1998; 32(6): 1648-56.
129. Levy RI, Brensike JF, Epstein SE, et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation. 1984; 69(2): 325-37.
130. Bruckert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis. 1993; 100(1): 91-102.
131. Kontopoulos AG, Athyros VG, Papageorgiou AA, et al. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coronary artery disease. 1996; 7(11): 843-50.
132. Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clinical chemistry. 2005; 51(12): 2264-73.
133. Tselepis AF, Rizzo M, Goudevenos IA. Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2). Current pharmaceutical design. 2011; 17(33): 3656-61.
134. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis. 2007; 193(2): 428-37.
135. Tsimihodimos V, Kakafika A, Tambaki AP, et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins. Journal of lipid research. 2003; 44(5): 927-34.
136. Florentin M, Tselepis AD, Elisaf MS, et al. Effect of non-statin lipid lowering and anti-obesity drugs on LDL subfractions in patients with mixed dyslipidaemia. Current vascular pharmacology. 2010; 8(6): 820-30.
137. Rizzo M, Mikhailidis DP. There is more to predicting vascular disease than just established risk factors. Current pharmaceutical design. 2011; 17(33): 3608-10.